Excipient Pedigree Verification - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Excipient Pedigree Verification
The author explains the background behind the excipient pedigree and how to implement its use.


Pharmaceutical Technology
pp. s28-s31

Verification of an excipient's pedigree and comprehensive incoming inspection data are important elements of supply-chain security. Without adequate implementation of both components, a pharmaceutical company can be exposed to nefarious activities comparable to a computer user whose Internet activities are unprotected by a firewall and antivirus software. As demonstrated by recent global supply-chain breaches, excipients are vulnerable to contamination, counterfeiting, and adulteration.


Checklist for supply-chain security
In May 2010, the International Pharmaceutical Excipient Council (IPEC) published criteria for excipient pedigrees (1). Pedigree criteria is based on good distribution practice (GDP) guides from the World Health Organization, IPEC, and the Product Quality Group (PQG), and cover auditing, Certificate of Analysis (CoA) data, distribution and holding, and more. The specific criteria can be implemented using the checklist for supply-chain security (see sidebar, "Checklist for supply-chain security"), and can be supported by the supply-chain security flow diagram shown in Figure 1. Use of these materials can help industry confirm that a purchased excipient arriving at the receiving dock has been produced in substantial conformance to excipient good manufacturing practice (GMP) and minimizes risk that the material has been tampered with or otherwise adulterated en-route.

Authenticity and quality


Figure 1: Supply-chain security flow diagram. GMP is good manufacturing practice; GDP is good distribution practice; CoA is Certificate of Analysis. (FIGURE IS COURTESY OF THE AUTHOR)
The first task in establishing excipient-pedigree authenticity is to identify the path from receipt of material back to the original excipient manufacturer. Unless the excipient is shipped directly from the manufacturer, the excipient user must trace the material's path from the final shipping point upstream to the manufacturer. This process can involve several stops along the distribution supply chain. At each stop, the pharmaceutical user should confirm through review of the shipping papers (i.e., papers included in the US Bill of Lading or Airway Bill) that the excipient lot in question was handled by the distributor and is traceable upstream to the previous stop. The path ends when the excipient manufacturer's shipping papers are identified, thus confirming the identity of the manufacturer and the full supply chain.

The second step in implementing the checklist involves performing an assessment of the manufacturer to confirm that the excipient was produced using an excipient GMP compliant quality system (2). In addition, each stop in the distribution supply chain must be assessed to confirm that the excipient was handled in compliance with applicable GMP and GDP requirements (3).

Industry best practice is to visit and audit the original excipient manufacturing site. Relying solely on responses from questionnaires no longer meets regulatory expectations under current GMP for supplier qualification. In a recent conference presentation, FDA announced that pharmaceutical users may soon be expected to audit their excipient suppliers themselves or to use a qualified third-party auditor (4). The pharmaceutical user should assess the third-party provider and confirm that it is qualified. At the conference, FDA said pharmaceutical manufacturers would be expected to audit their suppliers or use an accredited third party or qualified third party to do so. The American National Standards Institute (ANSI) has accredited an organization to provide certification to excipient GMPs that is accepted by FDA.

Before any on-site audit, it is advisable to send the supplier a pre-audit questionnaire that includes a request for the manufacturer to list the applicable quality system under which the excipient was manufactured. The pre-audit questionnaire can also facilitate the site audit by providing applicable background information. The questionnaire should identify the scope of operations conducted at the site. For the manufacturer, the response should identify contract operations, which also require auditing.

For the distributor, the response to the pre-audit questionnaire must identify the scope of its operation and whether other on-site operations might affect excipient quality. For example, the distributor may package bulk excipient or repackage excipient into smaller packages. The pharmaceutical manufacturer also must confirm that the distributor samples and tests the excipient to confirm there has been no contamination or degradation of the material. Once the pre-audit questionnaire is completed, the pharmaceutical user can finalize an audit plan and schedule the on-site audit.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
8%
Protecting the supply chain
40%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here